Recent com­pe­ti­tion on the PrEP mar­ket has caused a fur­ther drop of the price of gener­ic PrEP in Dutch phar­ma­cies. Dis­trib­u­tor Cen­tra­farm now offers gener­ic PrEP for €47,95 (incl. VAT, plus costs). Clients will pay about €54 a month for their prod­uct.

This brings PrEP with­in reach for many, if not most peo­ple. With a doctor’s pre­scrip­tion they can go to their local phar­ma­cy. It is impor­tant that the doc­tor writes ‘tenofovir/emtricitabine van Cen­tra­farm’ as a spe­cif­ic instruc­tion on the pre­scrip­tion. With­out it, it’s like­ly that a more expen­sive drug will be pro­vid­ed.

PrEP­nu goals not quite met
It’s with glad­ness that we wit­ness these devel­op­ments, but we are not yet done. To quote one of our own vol­un­teers: “Gee, prof­it dri­ven phar­ma­ceu­ti­cals have done more for access to PrEP than Dutch pol­i­tics.”

Indeed, we are still quite mad about the way politi­cians, par­tic­u­lar­ly VVD politi­cians, have con­stant­ly been obstruct­ing decent access to PrEP. We are still wait­ing for the Nation­al Health Council’s report, an advice due in March. It remains to be seen whether PrEP will then be cov­ered by health insur­ances. Exact­ly that is what is required for equal access to PrEP, in a safe and respon­si­ble set­ting.

Last updated 11/01/2018